MEDNAX (NYSE: MD ) is expected to report Q4 earnings on Jan. 31. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict MEDNAX's revenues will grow 17.0% and EPS will grow 9.2%.
The average estimate for revenue is $473.7 million. On the bottom line, the average EPS estimate is $1.30.
Last quarter, MEDNAX chalked up revenue of $473.1 million. GAAP reported sales were 16% higher than the prior-year quarter's $407.7 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at $1.32. GAAP EPS of $1.32 for Q3 were 11% higher than the prior-year quarter's $1.19 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 34.6%, 80 basis points worse than the prior-year quarter. Operating margin was 22.7%, 60 basis points worse than the prior-year quarter. Net margin was 13.9%, 40 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $1.82 billion. The average EPS estimate is $4.83.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 174 members out of 181 rating the stock outperform, and seven members rating it underperform. Among 62 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 59 give MEDNAX a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on MEDNAX is outperform, with an average price target of $80.36.
Is MEDNAX the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.